Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases

Inflammatory Bowel Diseases

Volumn 22, Issue 1, 2016, Pages 224-233

  Herfarth, Hans H ^a   Kappelman, Michael D ^a   Long, Millie D ^a   Isaacs, Kim L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

anti TNF therapy; Crohn's disease; IBD; methotrexate; ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; CREATININE; FOLIC ACID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISONE; STEROID; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ANTIBODY;

ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALLERGIC PNEUMONITIS; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; CONGENITAL MALFORMATION; COUGHING; CROHN DISEASE; DIARRHEA; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DYSPNEA; END STAGE LIVER DISEASE; FEVER; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS COMPLICATION; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEOPLASM; NONALCOHOLIC FATTY LIVER; PATIENT COMPLIANCE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; REVIEW; SIGMOIDOSCOPY; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; ULCERATIVE COLITIS; ADULT; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

ADULT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHOTREXATE; PROGNOSIS;

EID: 84964626535     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000589     Document Type: Review

References (112)

1. Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA. 1966;198:826-836.
2. Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-alpha. Clin Exp Rheumatol. 2010;28:S3-S8.
3. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
4. Manosa M, Naves JE, Leal C, et al. Does methotrexate induce mucosal healing in Crohn's disease? Inflamm Bowel Dis. 2010;16:377-378.
5. Carbonnel F, Colombel JF, Filippi J, et al. 745 methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial. Gastroenterology. 2015;148:S140.
6. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci. 1993;38:1851-1856.
7. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342: 1627-1632.
8. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's study Group Investigators. N Engl J Med. 1995;332:292-297.
9. Lemann M, Chamiot-Prieur C, Mesnard B, et al. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther. 1996; 10:309-314.
10. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110:1416-1421.
11. Saibeni S, Bollani S, Losco A, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44:123-127.
12. Herfarth HH, Long MD, Isaacs KL. Methotrexate: underused and ignored? Dig Dis. 2012;30(suppl 3):112-118.
13. Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:878-889.
14. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
15. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
16. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
17. Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483; quiz 464, 484.
18. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145: 1478.e1-1478.e5.
19. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441-1452.
20. Sunseri W, Hyams JS, Lerer T, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease. Inflamm Bowel Dis. 2014;20:1341-1345.
21. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978;3:1-13.
22. Herman RA, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989;78:165-171.
23. Stamp LK, Barclay M. Therapeutic drug monitoring in rheumatic diseases: utile or futile? Rheumatology (Oxford). 2014;53:988-997.
24. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1995;22:844-849.
25. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized doseresponse and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1597-1604.
26. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36:86-90.
27. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845-1849.
28. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645-648.
29. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a sixmonth, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73-81.
30. Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32:563-571.
31. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ./=15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549-1551.
32. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature. Ann Rheum Dis. 2009;68:1094-1099.
33. Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. [published online ahead of print May 15, 2015]. doi: 10.1136/annrheumdis-2014-206504.
34. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:57-63.
35. Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral methotrexate improves bioavailability: A pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:481-485.
36. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:91-94.
37. Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2005;40:445-449.
38. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001;15:35-44.
39. Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn's disease: A multicentre propensity score study. Gut. [published online ahead of print November 21, 2014]. doi: 10.1136/gutjnl-2014-307964.
40. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: A case for subcutaneous administration. J Gastroenterol Hepatol. 2008;23:954-958.
41. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009;30: 614-620.
42. Khan N, Abbas AM, Moehlen M, et al. Methotrexate in ulcerative colitis: A nationwide retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel Dis. 2013;19:1379-1383.
43. Hausmann J, Zabel K, Herrmann E, et al. Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis. 2010;16:1195-1202.
44. Gonzalez-Lama Y, Taxonera C, Lopez-Sanroman A, et al. Methotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The madrid experience. Eur J Gastroenterol Hepatol. 2012;24:1086-1091.
45. McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2014;8:CD003459.
46. Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2014;8: CD006884.
47. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013;4:CD000545.
48. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009:CD000067.
49. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
50. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: A randomised, investigator-blind study. Dig Liver Dis. 2003;35:619-627.
51. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999;46:1724-1729.
52. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: A double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997;92:2203-2209.
53. Domenech E, Manosa M, Navarro M, et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol. 2008;42:395-399.
54. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95: 1730-1734.
55. Charpignon C, Beau P. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol Clin Biol. 2008;32:153-157.
56. Seinen ML, Ponsioen CY, de Boer NK, et al. Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013;11:667-672.
57. Suares NC, Hamlin PJ, Greer DP, et al. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: A large singlecentre experience. Aliment Pharmacol Ther. 2012;35:284-291.
58. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut. 2002; 50:485-489.
59. Herfarth HH, Osterman MT, Isaacs KL, et al. Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis. 2010;16: 1421-1430.
60. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145:149-157 e2.
61. Higgins PD, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788.
62. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
63. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
64. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
65. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014;146:681-688 e1.
66. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
67. Narula N, Peyrin-Biroulet L, Colombel JF. Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT? Gastroenterology. 2014;146:608-611.
68. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr. 1998;132:830-835.
69. Boyle B, Mackner L, Ross C, et al. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010;51:714-717.
70. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol. 2007;102:2804-2812; quiz 2803, 2813.
71. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: A French multicenter study. Inflamm Bowel Dis. 2006;12:1053-1057.
72. Haisma SM, Lijftogt T, Kindermann A, et al. Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: A multicenter cohort study. J Crohns Colitis. 2015;9:305-311.
73. Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606-613.
74. Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn's disease. Clin Gastroenterol Hepatol. [published online ahead of print April 21, 2015]. doi: 10.1016/j.cgh.2015.04.010.
75. Din S, Dahele A, Fennel J, et al. Use of methotrexate in refractory Crohn's disease: The Edinburgh experience. Inflamm Bowel Dis. 2008;14:756-762.
76. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: A meta-analysis. Am J Gastroenterol. 2009;104:2089-2096.
77. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59:752-759.
78. Herfarth H, Tjaden C, Lukas M, et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut. 2006;55:1525-1526.
79. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987;14:1164-1171.
80. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-448.
81. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut. 2012;61:476-483.
82. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416-1423.
83. Fournier MR, Klein J, Minuk GY, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105:1620-1626.
84. Maybury CM, Jabbar-Lopez ZK, Wong T, et al. Methotrexate and liver fibrosis in people with psoriasis: A systematic review of observational studies. Br J Dermatol. 2014;171:17-29.
85. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis. 2009;68:1086-1093.
86. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 national psoriasis foundation consensus conference. J Am Acad Dermatol. 2009;60:824-837.
87. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-485.
88. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478-485.
89. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150-3156.
90. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:693-697.
91. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case-control study. J Hepatol. 2010;53:1035-1040.
92. Laharie D, Zerbib F, Adhoute X, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther. 2006;23:1621-1628.
93. Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Ther. 2014;40:938-948.
94. Conway R, Low C, Coughlan RJ, et al. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. Semin Arthritis Rheum. [published online ahead of print May 19, 2015]. doi: 10.1016/j.semarthrit.2015.05.003.
95. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis. 2009;68:1100-1104.
96. Morgacheva O, Furst DE. Use of MTX in the elderly and in patients with compromised renal function. Clin Exp Rheumatol. 2010;28:S85-S94.
97. Rondon F, Mendez O, Spinel N, et al. Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review. Clin Rheumatol. 2011;30:1379-1384.
98. Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis. 2010;4:211-214.
99. Conway R, Low C, Coughlan RJ, et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015;350:h1269.
100. Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66:803-812.
101. Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31:2360-2365.
102. Feagins LA, Kane SV. Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol. 2009;104:768-773.
103. Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: A prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101-1110.
104. Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55:1198-1206.
105. Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol. 2009;27: 678-684.
106. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal lowdose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014;53:757-763.
107. Loza E, Martinez-Lopez JA, Carmona L. A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol. 2009;27:856-862.
108. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-328.
109. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD000951.
110. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9-18.
111. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515-1524.
112. Kaffenberger BH, Kaffenberger JA, Wong H, et al. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate? Int J Dermatol. 2015;54:752-756.